Where does MAP Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), MAP Pharmaceuticals, Inc. ranks #18,873 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does MAP Pharmaceuticals, Inc. hold?

MAP Pharmaceuticals, Inc. holds 15 US utility patents granted between 2015 and 2019, spanning 8 technology areas.

What is MAP Pharmaceuticals, Inc.'s Innovation Score?

MAP Pharmaceuticals, Inc. has an Innovation Score of 25.4 out of 100 (17th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does MAP Pharmaceuticals, Inc. focus on?

MAP Pharmaceuticals, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 11 patents, ranking #1,740 of 6,058 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is MAP Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

MAP Pharmaceuticals, Inc.'s recent grant velocity is -100% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for MAP Pharmaceuticals, Inc.'s patents?

MAP Pharmaceuticals, Inc.'s patents average 9.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the MAP Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

MAP Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 15 granted patents across 8 technology areas, recorded in grant years 2015–2019. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, MAP ranks #18,873 of 49,997 tracked US assignees by granted-patent volume, with 15 patents across 8 technology areas.

#18,873
of 49,997 US assignees by volume: 17th percentile
by Innovation Score (25.4/100): 9.7
avg claims per patent: -100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R18873 · US Corporation #18,873 · 15 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 15 grants
MID-PACK #18,873/49,997
PHOTO-FINISH Lumencor
CPC-NARROW A61P · 8 areas
INNOV-THIN 25.4/100
CLAIMS-PAR 9.7 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Lumencor, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How MAP’s 25.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.6 pts (38%) Velocity 0.0 pts (0%) Breadth 10.0 pts (39%) Claim depth 5.8 pts (23%)

Qualcomm Incorporated · highest

85
MAP Pharmaceuticals · this assignee

25
3D Lighting… · lowest

7

What this shows MAP's Innovation Score is 25.4/100 (17th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for MAP?

Each dot is one of MAP’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). MAP’s own 9.7 claims/patent is at or below the 16.7 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

MAP vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where MAP's grants concentrate

MAP Pharmaceuticals, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 73.3% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (8 grants) versus a trough of 1 in 2019. By volume, MAP sits between Lumencor, Inc. and Material Science Co., Ltd..

Lumencor

15
Lumotive

15
M87

15
Maculogix

15
Mappedin

15
Marel Iceland EHF

15
Mastronardi Produ…

15
Material Science

15
MAP Pharmaceutica… ◀

15

What this shows MAP holds 15 patents at rank #18,866, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near MAP

By rank, the assignees closest to #18,866 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in MAP's primary technology class.

MAP's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

25 17th percentile higher than 17% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2019

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

MAP Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	8	53.3%
2016	4	26.7%
2017	2	13.3%
2019	1	6.7%

Which technologies does MAP Pharmaceuticals, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 11

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 10

C07D - Heterocyclic Compounds 8

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 5

B01F - Mixing, e.g. Dissolving, Emulsifying OR Dispersing 2

F04F - Pumping OF Fluid BY Direct Contact OF Another Fluid OR BY Using Inertia OF Fluid TO BE Pumped ; Siphons 2

F15D - Fluid Dynamics, i.e. Methods OR Means FOR Influencing THE Flow OF Gases OR Liquids 2

B05B - Spraying APPARATUS; Atomising APPARATUS; Nozzles 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

MAP Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

MAP Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 73.3% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #18,873 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare MAP Pharmaceuticals, Inc. against Lumencor, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 25.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.